House Biotech Caucus Endorses Key Biotechnology and Biomanufacturing Legislation

The bipartisan House BIOtech Caucus recently announced its first-ever legislative endorsements, backing two bills aimed at strengthening U.S. leadership in biotechnology and advanced manufacturing: the National Biotechnology Initiative Act (H.R. 2756) and the Biomanufacturing Excellence Act (H.R. 6089).

The endorsements signal growing recognition in Congress that biotechnology is central not only to healthcare innovation but also to national security, economic competitiveness, and supply chain resilience.

Together, these two measures address policy priorities highlighted by the National Security Commission on Emerging Biotechnology (NSCEB), which has urged the federal government to act quickly to coordinate biotechnology strategy across agencies and to expand domestic capacity for biopharmaceutical manufacturing.

The National Biotechnology Initiative Act (H.R. 2756) would establish a more coordinated, whole-of-government approach to biotechnology policy and investment.

As biotechnology increasingly shapes industries ranging from medicine to agriculture to advanced materials, policymakers have recognized that federal efforts must be better aligned across agencies responsible for research, regulation, manufacturing, workforce development, and national security. The legislation aims to improve coordination among federal programs and ensure that the United States maintains strategic leadership in biotechnology innovation.

The NSCEB has identified this type of cross-agency coordination as a critical priority, noting that fragmented federal efforts could undermine the nation’s ability to compete globally in emerging biotechnology sectors.

The Biomanufacturing Excellence Act (H.R. 6089) focuses on expanding and strengthening domestic biomanufacturing capabilities—an essential component of the life sciences innovation ecosystem.

Modern biologic medicines, vaccines, and advanced therapies require sophisticated manufacturing technologies and highly specialized facilities. Ensuring that these capabilities exist at scale within the United States has become a key policy priority in recent years.

The bill seeks to enhance domestic manufacturing infrastructure, support workforce development, and encourage innovation in advanced production technologies that can accelerate the delivery of new therapies to patients.

These actions directly align with the NSCEB’s call for strengthening America’s domestic biopharmaceutical innovation and manufacturing capacity, helping ensure that groundbreaking biomedical discoveries can be developed and produced within the United States.

While no members of Michigan’s congressional delegation are currently listed among the sponsors of these two bills - though MichBio will be seeking their support during upcoming Capitol Hill meetings - the policy priorities they address are highly relevant to Michigan’s growing life sciences sector.

Michigan’s bioscience ecosystem spans biopharmaceutical research, medical device innovation, diagnostics, and advanced manufacturing, with companies and research institutions across the state contributing to the development and production of next-generation therapies and technologies. Federal policies that strengthen biotechnology strategy and domestic manufacturing capacity can help support continued growth and investment in these sectors.

As Congress continues to evaluate legislation that shapes the future of biotechnology innovation, these efforts highlight the importance of sustained policy engagement to ensure that states like Michigan remain competitive in the evolving global bioscience landscape.

The BIOtech Caucus’ first legislative endorsements reflect a broader shift toward more strategic federal engagement in biotechnology policy. By supporting both a coordinated national biotechnology strategy and expanded domestic manufacturing capabilities, Congress is taking early steps to address priorities identified by national experts and industry leaders alike.

For the bioscience community, these developments represent an encouraging sign that policymakers are increasingly focused on strengthening the innovation infrastructure needed to advance biotechnology breakthroughs and bring life-changing therapies to patients.